Clinical Trial Detail

NCT ID NCT04074343
Title TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors University of California, Irvine
Indications

gastroesophageal cancer

gastric adenocarcinoma

Therapies

Irinotecan + Trifluridine-tipiracil hydrochloride

Age Groups: senior adult

No variant requirements are available.